Takeda Pharmaceutical Company Limited Transaction Price Allocated To Remaining Performance Obligations
Takeda Pharmaceutical Company Limited (TAK) had Transaction Price Allocated To Remaining Performance Obligations of JPY 23.61 billion as of 2025-03-31, per its 20-F filed 2025-06-25.
Financial Statements › Notes
ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations · last filed 2025-06-25
- 2025-03-31: Transaction Price Allocated To Remaining Performance Obligations 23.61B JPY.
- 2024-03-31: Transaction Price Allocated To Remaining Performance Obligations 8.30B JPY.
- 2023-03-31: Transaction Price Allocated To Remaining Performance Obligations 8.63B JPY.
- 2022-03-31: Transaction Price Allocated To Remaining Performance Obligations 50.91B JPY.
| Period end | Transaction Price Allocated To Remaining Performance Obligations |
|---|---|
| 2025-03-31 | 23.61B JPY 20-F · filed 2025-06-25 |
| 2024-03-31 | 8.30B JPY 20-F · filed 2025-06-25 |
| 2023-03-31 | 8.63B JPY 20-F · filed 2024-06-26 |
| 2022-03-31 | 50.91B JPY 20-F · filed 2023-06-28 |
| 2021-03-31 | 34.76B JPY 20-F · filed 2022-06-29 |
| 2020-03-31 | 5.79B JPY 20-F · filed 2021-06-29 |
| 2019-03-31 | 7.92B JPY 20-F · filed 2020-06-24 |
| 2018-04-01 | 4.86B JPY 20-F · filed 2019-06-27 |